Search: onr:"swepub:oai:DiVA.org:liu-193405" >
Intralymphatic immu...
-
Ahlbeck, LarsLinköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten,Region Östergötland, Allergicentrum US
(author)
Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial
- Article/chapterEnglish2023
Publisher, publication year, extent ...
-
WILEY,2023
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-193405
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-193405URI
-
https://doi.org/10.1111/cea.14307DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding Agencies|Astma- och Allergifoerbundet; Region OEstergoetland; Medical Research Council of Southeast Sweden (FORSS); Bergh Foundation
-
IntroductionThere is a need to evaluate the safety and efficacy of intralymphatic immunotherapy (ILIT) for inducing tolerance in patients with allergic rhinitis. MethodsThirty-seven patients with seasonal allergic symptoms to birch and grass pollen and skin prick test >3 mm and/or IgE to birch and timothy >0.35 kU/L were randomized to either ILIT, with three doses of 0.1 mL of birch pollen and 5-grass pollen allergen extracts on aluminium hydroxide (10,000 SQ-U/ml; ALK-Abello) or placebo using ultrasound-guided intralymphatic injections at monthly intervals. Daily combined symptom medical score and rhinoconjunctivitis total symptom score were recorded during the peak pollen seasons the year before and after treatment. Rhinoconjunctivitis total symptom score, medication score and rhinoconjunctivitis quality of life questionnaire were recorded annually starting 2 years after treatment. Circulating proportions of T helper cell subsets and allergen-induced cytokine and chemokine production were analysed using flow cytometry and ELISA. ResultsThere were no differences between the groups related to daily combined symptom medical score the year before and after treatment. Two years after ILIT (after unblinding), the actively treated group reported significantly fewer symptoms, lower medication use and improved quality of life than did the placebo group. After the pollen seasons the year after ILIT, T regulatory cell frequencies and grass-induced IFN-gamma levels increased only in the actively treated group. ConclusionIn this randomized controlled trial, ILIT with birch and grass pollen extract was safe and accompanied by immunological changes. Further studies are required to confirm or refute the efficacy of the treatment.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Ahlberg, EmelieLinköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten(Swepub:liu)emeah41
(author)
-
Stuivers, LinnLinköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten(Swepub:liu)n/a
(author)
-
Bjorkander, JanneFuturum, Sweden
(author)
-
Nyström Kronander, UllaRegion Östergötland, Allergicentrum US(Swepub:liu)ullny16
(author)
-
Retsas, PavlosLinköpings universitet,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Medicinkliniken ViN(Swepub:liu)pavre65
(author)
-
Govindaraj, DhanapalLinköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten(Swepub:liu)dhago86
(author)
-
Jenmalm, MariaLinköpings universitet,Avdelningen för inflammation och infektion,Medicinska fakulteten(Swepub:liu)marje18
(author)
-
Duchén, KarelLinköpings universitet,Avdelningen för barns och kvinnors hälsa,Medicinska fakulteten,Region Östergötland, Allergicentrum US(Swepub:liu)kardu59
(author)
-
Linköpings universitetAvdelningen för inflammation och infektion
(creator_code:org_t)
Related titles
-
In:Clinical and Experimental Allergy: WILEY53:8, s. 809-8200954-78941365-2222
Internet link
Find in a library
To the university's database